Overview

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

Status:
Active, not recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust
Treatments:
Acalabrutinib
Cyclophosphamide
Doxorubicin
Prednisolone
Vincristine